Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Narayan

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Advances in Radiation Oncology|June 16, 2018
Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704William F Regine, Kathryn Winter, Ross A Abrams, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003Vinai Gondi, Stephanie L Pugh, Minesh P Mehta, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Advances in Radiation Oncology|June 16, 2018
Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704William F Regine, Kathryn Winter, Ross A Abrams, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003Vinai Gondi, Stephanie L Pugh, Minesh P Mehta, et al.
Pageof 4